# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN-TD
- Date: 1946-06-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Okafor-Rosenthal, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Seven-week review: home blood pressure, work and symptoms. **S**

## History of present illness

Mr. Leonard returns seven weeks after intake. His home readings fell below 140/90 mmHg three weeks ago, and Dr. Okafor-Rosenthal cleared him by phone for full cards, as the cardiologist had advised. He has refereed four full cards since, drinking water between bouts, without breathlessness or chest tightness. His home readings over the past two weeks averaged 134/84 mmHg. He takes losartan-hydrochlorothiazide each morning and atorvastatin each evening without muscle aches, cough or lightheadedness. He walks briskly most mornings and eats less salted meat. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 134/84 mmHg over two weeks |
| Work | Four full cards without symptoms |
| Kidney function | Creatinine 1.06 mg/dL, potassium 3.9 mmol/L |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest tightness, palpitations, fainting or ankle swelling |
| Respiratory | Negative | No breathlessness at work |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |

3 systems reviewed. **S**

## Current medications

- Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning **S**
- Atorvastatin 40 mg tablet, one each evening **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/86 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74 kg; BMI 27.2 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 3.9 mmol/L; Urea nitrogen: 17 mg/dL; Creatinine: 1.06 mg/dL; eGFR: 84 mL/min/1.73 m²; Glucose: 95 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 3.9 mmol/L at this visit **S**
- Urea nitrogen: 15 mg/dL at baseline, 17 mg/dL at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.06 mg/dL at this visit **S**
- eGFR: 93 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 95 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 136/86 mmHg, pulse 72; weight 74.0 kg |
| Cardiovascular | Regular rhythm; fourth heart sound; no murmur; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease** (I11.9). Better, and symptom-free at full cards, but home readings of 134/84 mmHg are still above the target of 130/80 mmHg, which matters with left ventricular hypertrophy. **S**
   - Increase to losartan 100 mg with hydrochlorothiazide 25 mg each morning.
   - Basic metabolic panel in two weeks (lab slip given).
   - Keep drinking water between bouts, more on hot nights.
2. **Coronary atherosclerosis (calcium score 186)** (I25.10). On atorvastatin 40 mg for five weeks without side effects. **S**
   - Lipid panel at about nine weeks, at the preventive visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 136/86 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Two-week average 134/84 mmHg |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Completed today | Sodium 138, potassium 3.9 mmol/L, creatinine 1.06 mg/dL, eGFR 84; repeat two weeks after today's increase |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Due | At about nine weeks on atorvastatin |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None at four full cards |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Not indicated | No new symptoms |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Up to date | Repeat six to twelve months after the first |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 74.0 kg; brisk walks most mornings |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | No missed doses; no cough, lightheadedness or muscle aches |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Cleared for full cards three weeks ago; water between bouts |
| Self-management | Financial strain and medicine cost | Every visit | Completed today | Both medicines are generics he can afford |

## Goal progress

- Find the cause of the exertional breathlessness and chest tightness. Outcome by 1946-05-26: No inducible ischemia; symptoms from hypertensive heart disease with an exaggerated blood pressure response. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. In progress; target 1946-08-25. **S**
- LDL below 70 mg/dL and at least 50% lower than at intake. In progress; target 1946-07-28. **S**
- Keep refereeing full cards safely, without symptoms. In progress; target 1947-05-12. **S**
- Regression of left ventricular hypertrophy on a repeat echocardiogram. In progress; target 1947-05-26. **S**

## Medication changes

- Stopped: Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning **S**
- Started: Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026), American College of Cardiology and American Heart Association (Circulation 2026;153(17):e1154-e1276)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015), American Heart Association and American College of Cardiology (Circulation 2015;132(22):e298-e302)
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- Basic metabolic panel in two weeks. Preventive visit at the end of July with the lipid panel. Fifteen-week review in late August. **S**
- Next scheduled visit 1946-07-28: periodic adult preventive visit and recheck after the sick visit. **S**
